A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab

The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.

Physician inclusion criteria: * Physicians must be actively involved in the treatment/management of patients with MS * Consult with a minimum of 16 MS patients (\>5 in Japan and China, \>10 in Brazil) per month Patient inclusion criteria: Patients for whom physicians complete a Physician Completed Patient Record Form (PRF), and therefore are included in the pool of data for analysis, are based on the following criteria: * Patients who had a physician-made diagnosis of MS before or at the time of data collection * Patients must not currently be involved in a clinical trial * Patients ≥18 years old * For patients included in the ofatumumab sample, they must have been receiving ofatumumab for \>12 months at the time of data collection Exclusion criteria: • None